129 related articles for article (PubMed ID: 6541482)
1. Cisplatin metabolites in plasma, a study of their pharmacokinetics and importance in the nephrotoxic and antitumour activity of cisplatin.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1984 Oct; 33(19):3063-70. PubMed ID: 6541482
[TBL] [Abstract][Full Text] [Related]
2. Intracellular metabolites of cisplatin in the rat kidney.
Mistry P; Lee C; McBrien DC
Cancer Chemother Pharmacol; 1989; 24(2):73-9. PubMed ID: 2731314
[TBL] [Abstract][Full Text] [Related]
3. A study of the protective effect of chloride salts on cisplatin nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 Jul; 34(13):2363-9. PubMed ID: 4040367
[TBL] [Abstract][Full Text] [Related]
4. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
5. D-19466, a new cyclobutane-platinum complex with antitumor activity.
Voegeli R; Schumacher W; Engel J; Respondek J; Hilgard P
J Cancer Res Clin Oncol; 1990; 116(5):439-42. PubMed ID: 2229133
[TBL] [Abstract][Full Text] [Related]
6. The renal fractional clearance of platinum antitumour compounds in relation to nephrotoxicity.
Daley-Yates PT; McBrien DC
Biochem Pharmacol; 1985 May; 34(9):1423-8. PubMed ID: 4039567
[TBL] [Abstract][Full Text] [Related]
7. Preclinical studies on toxicity, antitumour activity and pharmacokinetics of cisplatin and three recently developed derivatives.
Lelieveld P; Van der Vijgh WJ; Veldhuizen RW; Van Velzen D; Van Putten LM; Atassi G; Danguy A
Eur J Cancer Clin Oncol; 1984 Aug; 20(8):1087-104. PubMed ID: 6381064
[TBL] [Abstract][Full Text] [Related]
8. Thioether suppression of cisplatin nephrotoxicity in the rat.
Jones MM; Basinger MA; Holscher MA
Anticancer Res; 1991; 11(1):449-53. PubMed ID: 2018382
[TBL] [Abstract][Full Text] [Related]
9. The relative nephrotoxicity of cisplatin, cis-[Pt(NH3)2(guanosine)2]2+, and the hydrolysis product of cisplatin in the rat.
Jones MM; Basinger MA; Beaty JA; Holscher MA
Cancer Chemother Pharmacol; 1991; 29(1):29-32. PubMed ID: 1742846
[TBL] [Abstract][Full Text] [Related]
10. The inhibition of renal ATPase by cisplatin and some biotransformation products.
Daley-Yates PT; McBrien DC
Chem Biol Interact; 1982 Jul; 40(3):325-34. PubMed ID: 6123388
[TBL] [Abstract][Full Text] [Related]
11. Relative effectiveness of some compounds for the control of cisplatin-induced nephrotoxicity.
Jones MM; Basinger MA; Holscher MA
Toxicology; 1991; 68(3):227-47. PubMed ID: 1896997
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and preclinical toxicological studies of 1,2-diaminocyclohexane(isocitrato)platinum(II).
Macquet JP; Cros S; Armand JP
Cancer Res; 1984 Sep; 44(9):3736-43. PubMed ID: 6540142
[TBL] [Abstract][Full Text] [Related]
13. L-methionine suppresses pathological sequelae of cis-platinum in the rat.
Basinger MA; Jones MM; Holscher MA
Fundam Appl Toxicol; 1990 Apr; 14(3):568-77. PubMed ID: 2340984
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of amino acid transport by cis-diamminedichloroplatinum(II) derivatives in L1210 murine leukemia cells.
Scanlon KJ; Safirstein RL; Thies H; Gross RB; Waxman S; Guttenplan JB
Cancer Res; 1983 Sep; 43(9):4211-5. PubMed ID: 6683587
[TBL] [Abstract][Full Text] [Related]
15. The comparative pharmacokinetics of carboplatin and cisplatin in mice and rats.
Siddik ZH; Newell DR; Boxall FE; Harrap KR
Biochem Pharmacol; 1987 Jun; 36(12):1925-32. PubMed ID: 3297068
[TBL] [Abstract][Full Text] [Related]
16. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
17. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin combined with tiopronin or sodium thiosulfate: cytotoxicity in vitro and antitumor activity in vivo.
Viale M; Zhang JG; Pastrone I; Mariggiò MA; Esposito M; Lindup WE
Anticancer Drugs; 1999 Apr; 10(4):419-28. PubMed ID: 10378678
[TBL] [Abstract][Full Text] [Related]
19. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
